

Figure S1: Efficacy of MBTA therapy in different size of Panc02 tumors (four independent experiments).




Figure S2: Growth curves of B16-F10 tumors in mice (n=4) completely cured from Panc02 tumors with MBTA therapy.





Figure S3: Survival analysis of mice previously treated with MBTA therapy after intracranial retransplantation. The survival analysis is presented as a Kaplan-Meier curve (\*\*\*)  $p < 0.001$ .





**Figure S5: Simultaneous MBTA therapy in the right tumor and hyalurodinase or hyaluronidase + anti-CD40 antibody therapy of the left parallel tumor.** C57BL/6 mice were subcutaneously injected with Panc02 cells in both right and left flanks. After 14 days, mice were randomized into 5 groups ( $n = 6/\text{group}$ ): the group treated with MBTA therapy (right tumor) and PBS (left tumor); the group treated with MBTA therapy (right tumor) and anti-CD40 (left tumor); the group treated with MBTA therapy (right tumor) and hyalurodinase (left tumor); the group treated with MBTA (right tumor) and hyalurodinase + anti-CD40 (left tumor); the group treated with PBS (right and left tumor). MBTA or PBS therapy of the right tumor were given intratumorally on days 0, 1, 2, 8, 9, 10, 16, 17, 18, 24, 25, and 26. Therapy of the left tumors (anti-CD40, hyalurodinase, hyalurodinase+anti-CD40) was applied intratumorally on days 1, 7, 14, 21, 28. The tumor volume of both tumors was measured with a caliper. **a** The tumor volume growth of the right and **(b)** the left parallel-treated tumors is presented as a growth curve ( $*p < 0.05$ ,  $***p < 0.005$ ). **c** The survival analysis is presented as a Kaplan-Meier curve.